

Erratum

Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning

MED Flowers, F Traina, B Storer, M Maris, WA Bethge, P Carpenter, F Appelbaum, R Storb, BM Sandmaier and PJ Martin

Bone Marrow Transplantation (2005) **35**, 535.
doi:10.1038/sj.bmt.1704862

Table 1 was published incorrectly in this article; the correct version is shown below.

Correction to: *Bone Marrow Transplantation* (2005) **35**, 277–282. doi:10.1038/sj.bmt.1704767

Table 1 Definition of serious acute or chronic GVHD

-
1. Death related to GVHD or its treatment
 - Organ failure caused by GVHD
 - Infection as the cause of death in patients with GVHD and corticosteroid treatment at prednisone-equivalent doses ≥ 1 mg/kg for ≥ 1 month before death
 - Corticosteroid treatment at prednisone-equivalent doses ≥ 0.5 mg/kg for ≥ 3 month before death, or
 - Exacerbation of GVHD and increased immunosuppressive treatment within 1 month before death
 - Other fatal complications of treatment (eg, pancreatitis)
 2. Severe disability because of GVHD
 - Respiratory compromise related to bronchiolitis obliterans or bronchiolitis obliterans with organizing pneumonia sufficient to impair normal activity of daily living (ADL)
 - Contractures that interfere with normal ADL because of GVHD
 3. ≥ 3 major infections in a calendar year during persistent GVHD
 - Sepsis
 - Pneumonia
 - Mold infections
 - Central nervous system infections
 4. Hospitalization for > 60 days in a single year because of GVHD
 5. Suicide or hospitalization for suicidal ideation because of GVHD or its treatment
-